Tofacitinib Phase 3 Trial in Rheumatoid Arthritis Reaches Primary Completion

A Phase 3 study involving tofacitinib (Xeljanz) as a comparator in subjects with rheumatoid arthritis reached primary completion on February 28, 2025. The trial, NCT06020144, is comparing TLL-018 to tofacitinib in patients who have had an inadequate response or intolerance to biologic DMARDs.

Background

Tofacitinib is an oral medication used in the treatment of various inflammatory conditions. In this study, it serves as a positive control arm. The trial focuses on subjects with rheumatoid arthritis, a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, and potential joint damage. The study population includes individuals who have previously shown an inadequate response or intolerance to biologic DMARDs (disease-modifying antirheumatic drugs).

Trial design

The study, identified as NCT06020144, is a Phase 3, randomized, double-blind, double-dummy, positive-controlled trial. It is designed to assess the safety and efficacy of TLL-018 in comparison to tofacitinib. The trial enrolled an estimated 450 participants diagnosed with rheumatoid arthritis. Participants in the study had active disease and experienced an inadequate response or intolerance to prior biologic DMARDs. The interventions being compared are TLL-018 and tofacitinib.

What this means

The primary completion of this Phase 3 trial indicates that the final data for the primary outcome measures have been collected. While specific efficacy or safety results are not yet available, this milestone signifies that the study has progressed through its data collection phase. The next steps typically involve data analysis, interpretation of results, and eventual public dissemination, which will provide insights into how TLL-018 compares to tofacitinib in this specific patient population.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06020144, titled "A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs," was posted on February 28, 2025 on clinicaltrials.gov.